29th week of 2013 patent applcation highlights part 33 |
Patent application number | Title | Published |
20130183223 | METHOD FOR PRODUCING HIGHER HYDRIDOSILANE COMPOUNDS - The present invention relates to a rapid and metal-free process for preparing high order hydridosilane compounds from low order hydridosilane compounds, wherein at least one low order hydridosilane compound (I) is thermally reacted in the presence of at least one hydridosilane compound (II) having a weight average molecular weight of at least 500 g/mol, to the hydridosilane compounds obtainable by the process and to their use. | 2013-07-18 |
20130183224 | AMMONIA SYNTHESIS CATALYST AND AMMONIA SYNTHESIS METHOD - The present invention provides a catalyst substance that is stable and performs well in the synthesis of ammonia, one of the most important chemical substances for fertilizer ingredients and the like. The catalyst substance exhibits catalytic activity under mild synthesis conditions not requiring high pressure, and is also advantageous from a resource perspective. Further provided is a method for producing the same. This catalyst comprises a supported metal catalyst that is supported on a mayenite type compound including conduction electrons of 10 | 2013-07-18 |
20130183225 | CRYSTAL GROWTH USING NON-THERMAL ATMOSPHERIC PRESSURE PLASMAS - A method and apparatus for bulk crystal growth using non-thermal atmospheric pressure plasmas. This method and apparatus pertains to growth of any compound crystal involving one or more crystal components in a liquid phase (also known as the melt or solution), in communication with a non-thermal atmospheric pressure plasma source comprised of one or more other crystal components. | 2013-07-18 |
20130183226 | GRAPHITE OXIDE, GRAPHENE OXIDE OR GRAPHENE, ELECTRIC DEVICE USING THE SAME AND METHOD OF MANUFACTURING THE SAME, AND ELECTRODIALYSIS APPARATUS - Highly-pure graphite oxide, graphene oxide, or graphene is mass-produced. Graphite is oxidized by an oxidizer, so that a graphite oxide solution is obtained, and electrodialysis is performed on the graphite oxide solution to remove aqueous ions, whereby the purity of graphite oxide is increased. Graphene oxide manufactured using the graphite oxide is mixed with powder, and the mixture is reduced, whereby graphene exhibiting conductive properties is yielded and the powder can be bonded. Such graphene can be used instead of a conduction auxiliary agent or a binder of a variety of batteries. | 2013-07-18 |
20130183227 | THERMOPLASTIC LIGNIN FOR PRODUCING CARBON FIBERS - A fusible lignin has a gas transition temperature in the range between 90 and 160° C. determined using differential scanning calorimetry (DSC), a molar mass distribution with a dispersivity of less than 28, determined using gel permeation chromatography (GPC), an ash content of less than 1 wt. %, and a proportion of volatile components of a maximum of 1 wt. %. Also provided is a precursor fiber based on the fusible lignin, as well as a method for the production thereof Also provided is a method for producing a carbon fiber from the precursor fiber. | 2013-07-18 |
20130183228 | Urchin-Like Copper Oxide Material Manufacturing Method - An urchin-like copper oxide material manufacturing method, comprising following steps: providing copper powder of length about 5 to 150 μm; placing the copper powder on an aluminum oxide plate to be heated up; and heating up the aluminum oxide plate in a reaction temperature of 300° C. to 700° C., to obtain urchin-like copper oxide material on the aluminum oxide plate. By employing the manufacturing method, it only requires a simple thermal oxidation process to synthesize and obtain various types of urchin-like copper oxides having good stability and reproducibility, hereby achieving excellent performance in various opto-electronic applications. | 2013-07-18 |
20130183229 | INTRODUCTION OF MESOPOROSITY INTO INORGANIC MATERIALS IN THE PRESENCE OF A NON-IONIC SURFACTANT - Compositions and methods for introducing mesoporosity into inorganic materials in the presence of a non-ionic surfactant are disclosed herein. Mesopores can be introduced into inorganic materials, such as zeolites, by treating the inorganic materials with a non-ionic surfactant. The resulting mesoporous inorganic materials can have a total 20 to 135 Å diameter mesopore volume of at least 0.05 cc/g and a crystalline content of at least 20 weight percent as measured by X-ray diffraction. | 2013-07-18 |
20130183230 | INTRODUCTION OF MESOPOROSITY INTO LOW SILICA ZEOLITES - Mesoporous X and A zeolites and methods for production thereof are disclosed herein. Such mesoporous zeolites can be prepared by contacting an initial zeolite with an acid in conjunction with a mesopore forming agent. The initial zeolite can have a framework silicon-to-aluminum content in the range of from about 1 to about 2.5. Additionally, such mesoporous zeolites can have a total 20 to 135 Å diameter mesopore volume of at least 0.05 cc/g. | 2013-07-18 |
20130183231 | INTRODUCTION OF MESOPOROSITY INTO ZEOLITE MATERIALS WITH SEQUENTIAL ACID, SURFACTANT, AND BASE TREATMENT - Compositions and methods for introducing mesoporosity into zeolitic materials employing sequential acid, surfactant, and base treatments are disclosed herein. Mesopores can be introduced into zeolitic materials, such as zeolites, by treatment with an acid and surfactant followed by treatment with a base. The resulting mesoporous zeolitic materials can have a total 20 to 135 Å diameter mesopore volume of at least 0.05 cc/g. Additionally, the resulting mesoporous zeolitic materials can have a total 0 to 20 Å micropore volume of at least 0.10 cc/g. | 2013-07-18 |
20130183232 | GLYCOXY SILANES AS A SOURCE OF SILICA AND SILICATE PRECIPITATES - The present invention discloses glycoxy silanes as a source of silica and silica precipitated by advantageous chemical reactions preferably beginning with biogenic silica. Alkoxy C—O—S | 2013-07-18 |
20130183233 | METHOD FOR MAKING GERMANOSILICATE SSZ-75 - The present invention is directing to a method for making a germanosilicate SSZ-75 molecular sieve using a tetramethylene-1,4-bis-(N-methylpyrrolidinium) dication as a structure directing agent. | 2013-07-18 |
20130183234 | Compositions Useful for Target, Detection, Imaging and Treatment, and Methods of Production and Use Thereof - Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein. | 2013-07-18 |
20130183235 | ALPHA-EMITTING COMPLEXES - The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes. | 2013-07-18 |
20130183236 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS - The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject. | 2013-07-18 |
20130183237 | THROMBIN INHIBITOR - The invention relates to thrombin inhibitors derived from the salivary glands of haematophagous arthropods and in particular to bivalent and trivalent thrombin inhibitors that act by interacting with thrombin at two or three different sites. | 2013-07-18 |
20130183238 | Formulation, Apparatus and Method for Stabilizing Radiopharmaceuticals - A formulation for stabilizing a radiopharmaceutical. The formulation includes a radiopharmaceutical (or a pharmaceutically acceptable salt thereof), a gas which has oxygen, a stabilizer, and a solvent. | 2013-07-18 |
20130183239 | ISOTOPIC CARBON CHOLINE ANALOGS - Novel choline-derived radiotracer (s) having an isotopic carbon for Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging of disease states related to altered choline metabolism (e.g., tumor imaging of prostate, breast, brain, esophageal, ovarian, endometrial, lung and prostate cancer—primary tumor, nodal disease or metastases). | 2013-07-18 |
20130183240 | IN VIVO IMAGING METHOD FOR CANCER - The present invention provides a method useful in the diagnosis and monitoring of cancer wherein there is an abnormal expression of PBR. The method of the invention is particularly useful in evaluating the severity of the cancer, e.g. PBR expression correlates with cell proliferation rates, metastatic potential, tumour aggressiveness, malignancy progression. The method of the invention can therefore be applied in the determination of likely disease progression and in making an associated prognosis. Furthermore, the method of the invention can find use in determining the likely success of certain therapeutic approaches, or in the evaluation of the efficacy of certain proposed new treatments. | 2013-07-18 |
20130183241 | PEPTIDES THAT HOME TO TUMOR LYMPHATIC VASCULATURE AND METHODS OF USING SAME - The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. | 2013-07-18 |
20130183242 | METHODS FOR IDENTIFYING TUMOR-SPECIFIC POLYPEPTIDES - The present invention provides methods for identifying tumor-specific polypeptides, polypeptides so identified, and methods for their use. | 2013-07-18 |
20130183243 | Methods and Device for Tuning Multiplexed Markers for Disease Assay - The present invention relates to a diagnostic device and methods of using the same for diagnostic assays for monitoring the presence of biological samples wherein the device allows for the determination of at least two assay components on one sensor. More specifically, the invention relates to a multi-marker electrochemical impedance spectroscopy sensor comprising a plurality of molecular recognition elements wherein the sensor comprises multiple different molecular recognition element types that are tuned in a manner that alters the frequency of the molecular recognition element type such that it is at a detectably different frequency to the frequency of other molecular recognition element types on the same sensor. | 2013-07-18 |
20130183244 | Rapid Diffusion of Large Polymeric Nanoparticles in the Mammalian Brain - Non-adhesive particles as large as 110 nm can diffuse rapidly in the brain ECS, if coated with hydrophilic coatings such as PEG coatings and preferably having neutral surface charge. The ability to achieve brain penetration with larger particles will significantly improve drug and gene delivery within the CNS since larger particles offer higher drug payload, improved drug loading efficiency, and significantly longer drug release durations. | 2013-07-18 |
20130183245 | METHODS OF TREATING CEREBRAL AMYLOID ANGIOPATHY - Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant. | 2013-07-18 |
20130183246 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT MICROFLUIDIC BEAD PRODUCTION - A system for producing microbeads includes a microfluidic device defining a supply channel and a shearing channel, a microbead precursor material disposed in the supply channel, a carrier fluid disposed in the shearing channel, and a pressure distribution system fluidly connected to each of the supply channel and the shearing channel to control at least relative pressures of the microbead precursor material and the carrier fluid. The supply channel includes a check valve adapted to be subjected to a bias pressure that is sufficient to close the check valve to flow of microbead precursor material when a supply pressure of the microbead precursor material is below a threshold pressure and is open to flow of the microbead precursor material when the supply pressure of the microbead precursor material is greater than the threshold pressure. An end of the supply channel opens into the shearing channel such that the microbead precursor material is sheared into droplets by the carrier fluid flowing through the shearing channel. A pressure of the carrier fluid is less than the bias pressure. The microbead precursor material and the carrier fluid are substantially immiscible. | 2013-07-18 |
20130183247 | FLUORESCENT CYANINE-POLYAMINE DERIVATIVES AS A DIAGNOSTIC PROBE - The invention relates to fluorescent derivatives of cyanines conjugated with a polyamine group, having formula (I), or a pharmaceutically acceptable salt thereof. The invention also relates to the method for preparing said derivatives, diagnostic compositions containing same and the use thereof as a diagnostic probe for the detection of cancer tumours, in particular in vivo. | 2013-07-18 |
20130183248 | METHOD AND KIT FOR DETECTION OF AUTOIMMUNE CHRONIC URTICARIA - Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria. | 2013-07-18 |
20130183249 | Stimulus Sensitive Magnetic Nanocomposite Using Pyrene Polymer, and Contrast Medium Composition Containing the Nanocomposite - Provided are a stimuli-sensitive magnetic nanocomposite using a pyrene-conjugated polymer and a method of preparing the same. Particularly, the stimuli-sensitive magnetic nanocomposite includes magnetic nanoparticles, an amphiphilic compound including at least one hydrophobic domain having a material having a pyrene structure and at least one hydrophilic domain and a pharmaceutically active ingredient. Here, the amphiphilic compound surrounds the pharmaceutically active ingredient, and the pharmaceutically active ingredient surrounds the magnetic nanoparticle and is chemically bound to a hydrophobic domain. Accordingly, the magnetic nanoparticles and the pharmaceutically active ingredient are stable in an aqueous solution, have excellent magnetic properties and a rapid drug release behavior due to a specific stimulus, and exhibit targeting according to a tissue-specific binding component. Thus, the stimuli-sensitive magnetic nanocomposite has target specificity and serves as a contrast composition or pharmaceutical composition. | 2013-07-18 |
20130183250 | BODY CAVITY FOAMS - The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents. | 2013-07-18 |
20130183251 | PENETRATING PHARMACEUTICAL FOAM - The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration. | 2013-07-18 |
20130183252 | COMPOUNDS THAT INHIBIT (BLOCK) BITTER TASTE IN COMPOSITION AND METHODS OF MAKING SAME - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof as bitter taste blockers or flavor modulators in, e.g., coffee and coffee flavored foods, beverages and medicaments. Also, the present invention relates to the discovery of a compound that antagonizes numerous different human T2Rs and the use thereof in assays and as a bitter taste blocker in compositions for ingestion by humans and animals. | 2013-07-18 |
20130183253 | Dual Component Oral Composition For Enhancing Remineralization of Teeth - An dual oral composition is provided having a first peroxide-containing component and a second bicarbonate-containing component having exceptional anti-plaque and anti-bacterial action with re-mineralization properties. | 2013-07-18 |
20130183254 | METHODS AND COMPOSITIONS FOR PROMOTING HAIR GROWTH - Methods and compositions related to promoting hair growth are described. | 2013-07-18 |
20130183255 | AVOCADO FLESH AND/OR SKIN EXTRACT RICH IN POLYPHENOLS AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME - The invention relates to an avocado extract rich in polyphenols, containing at least 10% by weight of polyphenols, expressed in gallic acid equivalent relative to the dry extract obtained, wherein said polyphenols contain procyanidins, cafeic acid and cafeic acid derivatives, typically in a proportion of at least 70% by weight, expressed in gallic acid equivalent relative to the total polyphenol content by weight. The invention also relates to a composition comprising an extract according to the invention as active agent and a suitable excipient. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which consists in administering such a composition or such an extract. | 2013-07-18 |
20130183256 | SILICONE SCAR TREATMENT PREPARATION - Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives. | 2013-07-18 |
20130183257 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN APPEARANCE - Skin conditioning compositions comprising a C4 to C30 monoalkyl-, dialkyl, monoalkanoyl- or dialkanoyl-substituted isohexide are found to exhibit a marked effect on skin hydration and barrier function homeostasis thereby improving skin appearances. | 2013-07-18 |
20130183258 | SILICONE-FREE ANTIPERSPIRANT COMPOSITIONS AND METHODS FOR MANUFACTURING SILICONE-FREE ANTIPERSPIRANT COMPOSITIONS - Silicone-free antiperspirant compositions and methods for fabricating silicone-free antiperspirant compositions are provided. In accordance with an exemplary embodiment, an antiperspirant composition includes an active antiperspirant compound, stearyl alcohol, a C14-C16 fatty alcohol, and a carrier fluid. The carrier fluid is composed of a first volatile hydrocarbon component selected from a C12-C14 hydrocarbon, a second volatile hydrocarbon selected from a C13-C16 hydrocarbon, and at least one non-volatile hydrocarbon component. | 2013-07-18 |
20130183259 | HUMAN SEBUM MIMETICS DERIVED FROM BOTANICAL SOURCES AND METHODS FOR MAKING THE SAME - Human sebum mimetics and methods for producing human sebum mimetics are provided. In one exemplary embodiment, a human sebum mimetic comprises a wax ester derived from interesterification of refined botanical oil comprising palmitoleic acid and refined jojoba oil, a phytosterol, and phytosqualene. A method for producing a human sebum mimetic comprises mixing refined macadamia oil and refined jojoba oil, interesterifying the refined macadamia oil and the refined jojoba oil, adding a phytosterol alter the interesterifying, and adding phytosqualene after the interesterifying, | 2013-07-18 |
20130183260 | HUMAN SEBUM MIMETICS DERIVED FROM BOTANICAL SOURCES AND METHODS FOR MAKING THE SAME - Human sebum mimetics and methods for producing human sebum mimetics are provided. In one exemplary embodiment, a human sebum mimetic comprises a wax ester derived from interesterification of refined botanical oil comprising palmitoleic acid and refined jojoba oil, a phytosterol, phytosqualene, and/or phytosteryl macadamiate. Method for producing a human sebum mimetic comprises mixing refined macadamia oil and refined jojoba oil, interesterifying the refined macadamia oil and the refined jojoba oil, adding a phytosterol, adding phytosteryl macadamiate, and adding phytosqualene after the interesterifying. | 2013-07-18 |
20130183261 | METHOD AND COMPOSITION FOR DELIVERING ACTIVE INGREDIENT INTO AIR, AND USE THEREOF - The present invention is directed to a method and a spray composition for delivering an active ingredient into air. The spray composition comprises a carrier composition containing a glycol ether having a structure represented by the following General Formula: R | 2013-07-18 |
20130183262 | ANTIMICROBIAL POLYMERIC COMPOSITIONS - A compound having the formula: | 2013-07-18 |
20130183263 | PHARMACEUTICAL COMPOSITIONS AND METHODS - Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. | 2013-07-18 |
20130183264 | Antagonists of IL-6 to raise albumin and/or lower crp - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. | 2013-07-18 |
20130183265 | MIA-2 PROTEIN - The present invention relates to the human and murine melanoma inhibitory activity protein-2 (MIA-2) and to the nucleic acids encoding said proteins including a method for producing such proteins by recombinant techniques. The invention also relates to methods for utilizing such proteins for tissue regeneration, tumor treatment including to control the proliferation and differentiation of liver cells in vivo and in vitro. The invention further relates to diagnostic assays including the human and murine antibodies or aptamers and their use in therapy and diagnosis. Further it relates to diagnostic assays applying specific primers for the diagnostic of liver disease. | 2013-07-18 |
20130183266 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - A compound is represented by Structural Formula (I): | 2013-07-18 |
20130183267 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 2013-07-18 |
20130183268 | DRUG COMBINATIONS WITH FLUORO-SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS - The present invention relates to drug combinations and pharmaceutical compositions for treating hyperproliferative disorders such as cancer including non-small cell lung carcinoma, said drug combination comprising (1) a fluoro-substituted-diaryl urea of Formula (I), (2) at least one antifolate and optionally (3) at least one platinum complex antineoplastic nucleic acid binding agent, where any of these components can be present in the form of a pharmaceutically acceptable salt or other derivative thereof. | 2013-07-18 |
20130183269 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein. | 2013-07-18 |
20130183270 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents. | 2013-07-18 |
20130183271 | Methods and Compositions Concerning Poxviruses and Cancer - The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer. | 2013-07-18 |
20130183272 | MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO - The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and method sof treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies. | 2013-07-18 |
20130183273 | NATIVE WHARTON'S JELLY STEM CELLS AND THEIR PURIFICATION - Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided. | 2013-07-18 |
20130183274 | MAINTENANCE AND PROPAGATION OF MESENCHYMAL STEM CELLS - Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same. | 2013-07-18 |
20130183275 | Novel Use of Cryptotanshinone - Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. | 2013-07-18 |
20130183276 | METHODS AND COMPOSITIONS FOR TREATING HIV - The invention features nucleic acid constructs encoding chimeric immune T-cell receptors (CIRs) that are useful for treating HIV in patients. In general, the CIRs contain an extracellular domain which targets HIV or HIV infected cells (e.g., the extracellular domain of CD4), a transmembrane domain, and a cytoplasmic domain for mediating T-cell activation (e.g., CD3 zeta and/or the partial extracellular domain of CD28). The invention also features the use of host cells expressing CIRs in the treatment of HIV. | 2013-07-18 |
20130183277 | NUTRIENT COMPOSITIONS AND METHODS FOR ENHANCED EFFECTIVENESS OF THE IMMUNE SYSTEM - Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine. | 2013-07-18 |
20130183278 | METHOD FOR DIAGNOSIS - The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD as opposed to another neurodegenerative disease. The method of the invention comprises measuring the concentration of α-synuclein (α-syn) and the concentration of unphosphorylated tau (tau) and/or phosphorylated tau (p-tau) in a cerebrospinal fluid sample taken from an individual. The method also comprises calculating the ratio of the concentration of tau and/or p-tau to the concentration of α-syn, and thereby determining whether or not the individual has PD. | 2013-07-18 |
20130183279 | Fibrin Formulations for Wound Healing - Fibrin formulations, fibrin matrices and kits for wound healing, use of the formulation, matrices and foams, and kits and methods of using thereof, are described herein. In a preferred aspect, the compositions are suitable for use for local administration. In another preferred aspect, the compositions are also suitable for use in methods for forming enhanced controlled delivery fibrin matrices and foams. | 2013-07-18 |
20130183280 | STABILIZED FACTOR VIII VARIANTS - The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules. | 2013-07-18 |
20130183281 | METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS - Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2). | 2013-07-18 |
20130183282 | Meganuclease variants cleaving a DNA target sequence from the rhodopsin gene and uses thereof - The invention relates to meganuclease variants which cleave a DNA target sequence from the human Rhodopsin gene (RHO), to vectors encoding such variants, to a cell, an animal or a plant modified by such vectors and to the use of these meganuclease variants and products derived therefrom for genome therapy, ex vivo (gene cell therapy) and genome engineering including therapeutic applications and cell line engineering. | 2013-07-18 |
20130183283 | Method for Treating Systemic DNA Mutation Disease - The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient. | 2013-07-18 |
20130183284 | Method for Treating Systemic Bacterial, Fungal and Protozoan Infection - The invention is directed to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a DNase enzyme into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said DNase enzyme destroys extracellular DNA in said blood of said patient, said DNase enzyme being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient. | 2013-07-18 |
20130183285 | Methods for accelerating the healing of connective tissues injuries and disorders - The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), including pooled ACCS, and Physiologic Cytokine Solution (PCS). | 2013-07-18 |
20130183286 | Composition and method for preventing/decreasing respiratory illness - A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air. The adherence inhibiting material can be formulated for use in a variety of ways such as an oral spray or a nasal spray. These formulations can be effective to prevent or reduce respiratory illnesses in animals and humans. | 2013-07-18 |
20130183287 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF - The disclosure relates to the field of GPCR structure biology and signaling. In particular, it relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, it provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains hereof can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, also encompassed are the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases. | 2013-07-18 |
20130183288 | NON-FUCOSYLATED ANTIBODIES - The present invention provides non-fucosylated therapeutic antibodies. More particularly, the invention provides non-fucosylated anti-CD20, anti-CD23 and anti-CD80 antibodies, which show enhanced antibody effector functions. Also provided are cells expressing the non-fucosylated antibodies and therapeutic methods using the non-fucosylated antibodies. | 2013-07-18 |
20130183289 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) - The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses. | 2013-07-18 |
20130183290 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODY - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly | 2013-07-18 |
20130183291 | CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF - The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments. | 2013-07-18 |
20130183292 | TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY - The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody. | 2013-07-18 |
20130183293 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE , AND/OR FEVER - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2013-07-18 |
20130183294 | METHODS OF USING FGF19 MODULATORS - Provided herein are methods of using FGF19 modulators and/or bile acid metabolism biomarkers. | 2013-07-18 |
20130183295 | THERAPY-ENHANCING GLUCAN - This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition. | 2013-07-18 |
20130183296 | Targeted Identification of Immunogenic Peptides - This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor as at proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody. | 2013-07-18 |
20130183297 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD - The method of treating a person having a cancer selected from carcinoma, sarcoma or hematopoietic cancer by administering (a) an effective amount of at least one anti-cancer drug selected from the group consisting of an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and a Raf kinase inhibitor and (b) an effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride provided that said carcinoma is not lung cancer when an EGFR inhibitor is erlotinib. The invention also provides a pharmaceutical composition that may be used in practicing said method. | 2013-07-18 |
20130183298 | Methods of Treating Hepatitis With Anti-TNF alpha Antibodies - Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided. | 2013-07-18 |
20130183299 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF - Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample. | 2013-07-18 |
20130183300 | METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2013-07-18 |
20130183301 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall survival and/or progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. | 2013-07-18 |
20130183302 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. | 2013-07-18 |
20130183303 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. | 2013-07-18 |
20130183304 | NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES - The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). | 2013-07-18 |
20130183305 | CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO - The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLD-N6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis. | 2013-07-18 |
20130183306 | ANTI-CD19 ANTIBODY HAVING ADCC FUNCTION WITH IMPROVED GLYCOSYLATION PROFILE - The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease. | 2013-07-18 |
20130183307 | ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY - Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases. | 2013-07-18 |
20130183308 | THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal. | 2013-07-18 |
20130183309 | Fragments, Mutants and Chimeric Fusion Proteins of Leptin For Treating Alzheimer's Disease - The described invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy, in mammalian subjects using a composition comprising therapeutically effective amount of a leptin, leptin mimic, leptin derivative, leptin agonist, or AMP-dependent protein kinase activator, alone, or in combination with, one or more lipolytic/antilipogenic compounds. It further relates to methods for improving cognitive function using a composition comprising a therapeutically effective amount of leptin, a leptin mimic, a leptin derivative, an AMP-dependent protein kinase activator, a leptin agonist, a leptin blocker, a mimic of a leptin blocker, a leptin antagonist, an AMP-dependent protein kinase inhibitor; or a pharmaceutically acceptable salt thereof. | 2013-07-18 |
20130183310 | ADMINISTERING ANTI-PLACENTAL GROWTH FACTOR ANTIBODIES - The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF | 2013-07-18 |
20130183311 | BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agents are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided. | 2013-07-18 |
20130183312 | MODULAR TARGETED THERAPEUTIC AGENTS AND METHODS OF MAKING SAME - Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. | 2013-07-18 |
20130183313 | HUMAN MONOCLONAL ANTIBODIES TO THE THYROTROPIN RECEPTOR WHICH ACT AS ANTAGONISTS - The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention. | 2013-07-18 |
20130183314 | HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B - This invention provides antibodies that specifically bind and neutralize | 2013-07-18 |
20130183315 | Antibodies that bind to OX40 and their uses - The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6. | 2013-07-18 |
20130183316 | AGONISTIC ANTIBODY TO CD27 - The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim | 2013-07-18 |
20130183317 | G-PROTEIN COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1 AS A CANCER BIOMARKER - A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed. | 2013-07-18 |
20130183318 | METHODS AND COMPOSITIONS FOR THE INHIBITION OF STAT5 IN PROSTATE CANCER CELLS - The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells. | 2013-07-18 |
20130183319 | FGFR4 ANTIBODIES - The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression. | 2013-07-18 |
20130183320 | ANTI-LRP5 ANTIBODIES AND METHODS OF USE - The invention provides anti-LRP5 antibodies and methods of making and using the same. | 2013-07-18 |
20130183321 | GITR BINDING MOLECULES AND USES THEREFOR - The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention. | 2013-07-18 |
20130183322 | IMMUNOSUPPRESSIVE DRUG COMBINATION FOR A STABLE AND LONG TERM ENGRAFTMENT - A method of treating a subject in need of a cell or tissue transplant is disclosed. The method comprising (a) transplanting a non-syngeneic cell or tissue transplant into the subject, wherein the transplant comprises bone marrow or lymphoid cells; and (b) administering to the subject a therapeutically effective amount of an immunosuppressive regimen comprising a Sphingosine 1-Phosphate Receptor Agonist, a B7 molecule inhibitor and a CD2/CD58 pathway inhibitor, thereby treating the subject. | 2013-07-18 |